KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  232.99
-5.63 (-2.36%)
AAPL  276.49
+7.01 (2.60%)
AMD  200.19
-41.92 (-17.31%)
BAC  55.38
+0.93 (1.71%)
GOOG  333.34
-7.36 (-2.16%)
META  668.99
-22.71 (-3.28%)
MSFT  414.19
+2.98 (0.72%)
NVDA  174.19
-6.15 (-3.41%)
ORCL  146.67
-8.00 (-5.17%)
TSLA  406.01
-15.95 (-3.78%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.